References
Dayer P, Balant L, Küpfer F, Courvoisier F, Fabre J (1983) Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents. Eur J Clin Pharmacol 24: 797–799
Idle JR, Sever PS (1983) Treatment of angina pectoris with nifedipine. Br Med J 286: 1978–1979
Idle JR, Oates NS, Shah RR, Smith RL (1983) Protecting poor metabolisers, a group at high risk of adverse drug reactions. Lancet 1: 1388
Jack DB, Quarterman CP, Zaman R, Kendall MJ (1982) Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol 23: 37–42
Jack DB, Wilkins MR, Quarterman CP (1983) Lack of evidence for polymorphism in metoprolol metabolism. Br J Clin Pharmacol 16: 188–190
Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF (1982) Oxidation phenotype — a major determinant of metoprolol metabolism and response. N Engl J Med 307: 1558–1560
Lennard MS, Ramsay LE, Silas JH, Tucker GT, Woods HF (1983) Protecting the poor metaboliser: Clinical consequences of genetic polymorphism of drug oxidation. Pharm Int 4: 53–57
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jack, D.B., Wilkins, M.R., Kendall, M.J. et al. Variability of plasma drug concentrations: Some observations. Eur J Clin Pharmacol 25, 569–570 (1983). https://doi.org/10.1007/BF00542131
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00542131